Interactions among smoking, obesity, and symptoms of acid reflux in Barrett's esophagus

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 11 I, 2005, Pages 2481-2486

  Smith, Kylie J ^a   O'Brien, Suzanne M ^a   Smithers, B Mark ^a   Gotley, David C ^a   Webb, Penelope M ^a   Green, Adèle C ^a   Whiteman, David C ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; AUSTRALIA; BARRETT ESOPHAGUS; CANCER RISK; CASE CONTROL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DYSPLASIA; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; OBESITY; POPULATION RESEARCH; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZATION; SELF REPORT; SMOKING; SYMPTOM; TELECOMMUNICATION;

AGED; BARRETT ESOPHAGUS; CASE-CONTROL STUDIES; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; OBESITY; RISK FACTORS; SMOKING;

EID: 28644440798     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-05-0370     Document Type: Article

References (41)

1. Falk GW. Barrett's esophagus. Gastroenterology 2002;122:1569-91.
2. Murray L, Watson P, Johnston B, et al. Risk of adenocarcinoma in Barrett's oesophagus: population based study. Br Med J 2003;327:534-5.
3. Conio M, Cameron AJ, Romero Y, et al. Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota. Gut 2001;48:304-9.
4. Shaheen NJ. Advances in Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology 2005;128:1554-66.
5. Blot WJ, McLaughlin JK. The changing epidemiology of esophageal cancer. Semin Oncol 1999;26:2-8.
6. Vizcaino AP, Moreno V, Lambert R, Parkin DM. Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer 2002;99:860-8.
7. Botterweck AA, Schouten LJ, Volovics A, et al. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 2000;29:645-54.
8. Lord RV, Law MG, Ward RL, et al. Rising incidence of oesophageal adenocarcinoma in men in Australia. J Gastroenterol Hepatol 1998;13:356-62.
9. Prach AT, MacDonald TA, Hopwood DA, Johnston DA. Increasing incidence of Barrett's oesophagus: education, enthusiasm, or epidemiology? Lancet 1997;350:933.
10. Lagergren J, Bergstrom R, Lindgren A, Nyren O. The role of tobacco, snuff and alcohol use in the aetiology of cancer of the oesophagus and gastric cardia. Int J Cancer 2000;85:340-6.
11. Gammon MD, Schoenberg JB, Ahsan H, et al. Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1997;89:1277-84.
12. Brown LM, Swanson CA, Gridley G, et al. Adenocarcinoma of the esophagus: role of obesity and diet. J Natl Cancer Inst 1995;87:104-9.
13. Chow WH, Blot WJ, Vaughan TL, et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1998;90:150-5.
14. Lagergren J, Bergstrom R, Adami HO, Nyren O. Association between medications that relax the lower esophageal sphincter and risk for esophageal adenocarcinoma. Ann Intern Med 2000;133:165-75.
15. Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 2002;97:1888-95.
16. Westbrook JI, Talley NJ, Westbrook MT. Gender differences in the symptoms and physical and mental well-being of dyspeptics: a population based study. Qual Life Res 2002;11:283-91.
17. Westbrook JI, Talley NJ. Empiric clustering of dyspepsia into symptom subgroups: a population-based study. Scand J Gastroenterol 2002;37:917-23.
18. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31.
19. Chow WH, Finkle WD, McLaughlin JK, et al. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA 1995;274:474-7.
20. Rothman KJ. Modern epidemiology. 1st ed. Boston (MA): Little, Brown, and Company; 1986.
21. Conio M, Filiberti R, Blanchi S, et al. Risk factors for Barrett's esophagus: a case-control study. Int J Cancer 2002;97:225-9.
22. Campos GM, DeMeester SR, Peters JH, et al. Predictive factors of Bairett esophagus: multivariate analysis of 502 patients with gastroesophageal reflux disease. Arch Surg 2001;136:1267-73.
23. Lieberman DA, Oehlke M, Helfand M. Risk factors for Barrett's esophagus in community-based practice. GORGE consortium. Gastroenterology Outcomes Research Group in Endoscopy. Am J Gastroenterol 1997;92:1293-7.
24. Talley NJ, Quan C, Jones MP, Horowitz M. Association of upper and lower gastrointestinal tract symptoms with body mass index in an Australian cohort. Neurogastroenterol Motil 2004;16:413-9.
25. Nilsson M, Johnsen R, Ye W, et al. Obesity and estrogen as risk factors for gastroesophageal reflux symptoms. JAMA 2003;290:66-72.
26. Delgado-Aros S, Locke GR III, Camilleri M, et al. Obesity is associated with increased risk of gastrointestinal symptoms: a population-based study. Am J Gastroenterol 2004;99:1801-6.
27. Vaughan TL, Davis S, Kristal A, Thomas DB. Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia: adenocarcinoma versus squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 1995;4:85-92.
28. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U S. adults. N Engl J Med 2003;348:1625-38.
29. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004;4:579-91.
30. Adami HO, Trichopoulos D. Obesity and mortality from cancer. N Engl J Med 2003;348:1623-4.
31. Corley DA, Kerlikowske K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003;124:47-56.
32. Farrow DC, Vaughan TL, Hansten PD, et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 1998;7:97-102.
33. Morgan G, Vainio H. Barrett's oesophagus, oesophageal cancer and colon cancer: an explanation of the association and cancer chemopreventive potential of non-steroidal anti-inflammatory drugs. Eur J Cancer Prev 1998;7:195-9.
34. Jankowski J, Moayyedi P. Re: Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus. J Natl Cancer Inst 2004;96:885-7.
35. Heath EI, Canto MI, Wu TT, et al. Chemoprevention for Barrett's esophagus trial. Design and outcome measures. Dis Esophagus 2003;16:177-86.
36. Sharma P, McQuaid K, Dent J, et al. A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology 2004;127:310-30.
37. El-Serag HB, Petersen NJ, Carter J, et al. Gastroesophageal reflux among different racial groups in the United States. Gastroenterology 2004;126:1692-9.
38. Nandurkar S, Locke GR III, Murray JA, et al. Rates of endoscopy and endoscopic findings among people with frequent symptoms of gastroesophageal reflux in the community. Am J Gastroenterol 2005;100:1459-65.
39. Shaheen N. Is there a "Barrett's iceberg?" Gastroenterology 2002;123:636-9.
40. Rogers A, Murtaugh MA, Edwards S, Slattery ML. Contacting controls: are we working harder for similar response rates, and does it make a difference? Am J Epidemiol 2004;160:85-90.
41. Australian Bureau of Statistics. National Health Survey 2001: summary of results. Canberra: Australian Bureau of Statistics; 2002.